Modulating the Gut-Ovarian Axis: Mechanistic Rationale and the Limits of Current Evidence for Probiotics in Female Reproductive Aging.

Abstract

Female reproductive aging is characterized by progressive follicular depletion, deterioration of oocyte quality, and endocrine decline, with oxidative stress, mitochondrial dysfunction, immune-inflammatory remodeling, and granulosa-cell loss contributing to ovarian functional deterioration. This critical narrative review, supported by a structured literature search, evaluates mechanistic, preclinical, and human evidence for probiotic and microbiota-targeted modulation of the gut-ovarian axis. The current evidence base remains predominantly preclinical. In premature ovarian insufficiency (POI), polycystic ovary syndrome (PCOS), chemotherapy-induced ovarian injury, and reproductive-aging models, selected interventions have modified intestinal microbial ecology, barrier function, microbial metabolites, and systemic immune-metabolic-endocrine signaling, with model-specific effects on ovarian redox homeostasis, granulosa-cell survival, follicular development, mitochondrial function, and oocyte-related outcomes. Mechanistic support is strongest where gut dependency, metabolite supplementation, or related causal approaches have been demonstrated, but responses remain highly strain-, model-, dose-, route-, and host-dependent. Human trials in PCOS and menopause-related or reproductive settings have reported changes in selected metabolic, hormonal, menstrual, symptom, quality-of-life, and fertility-related outcomes; however, our structured literature and trial-registry searches did not identify a randomized human trial specifically designed to test whether probiotic or microbiota-targeted intervention slows the longitudinal physiological loss of ovarian reserve or delays physiological ovarian aging. Findings from disease models, fecal microbiota transplantation, or other experimental interventions should therefore not be equated with the efficacy of oral probiotic foods or supplements. Current evidence supports biological plausibility and translational potential rather than established ovarian anti-aging efficacy. Future studies should evaluate well-characterized oral strains using prespecified ovarian-aging-relevant endpoints, mechanistic biomarkers, and standardized safety assessment.